MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
MediWound (Nasdaq: MDWD), a leader in enzymatic therapeutics for tissue repair, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Ofer Gonen will engage in a fireside chat on Wednesday, October 16, 2024, at 9:30 a.m. ET. The discussion will be hosted by Michael Okunewitch, Senior Biotechnology Analyst at Maxim.
Interested parties can register to attend the virtual fireside chat through the provided link. Additionally, the MediWound management team will be available for one-on-one meetings during the summit. Investors wishing to schedule a meeting are advised to contact their Maxim representative.
MediWound (Nasdaq: MDWD), un leader nelle terapie enzimatiche per la riparazione dei tessuti, ha annunciato la sua partecipazione al Maxim Healthcare Virtual Summit 2024. Il CEO Ofer Gonen parteciperà a una conversazione informale il mercoledì 16 ottobre 2024, alle 9:30 a.m. ET. La discussione sarà moderata da Michael Okunewitch, Analista Senior di Biotecnologie presso Maxim.
Le parti interessate possono registrarsi per partecipare alla conversazione virtuale attraverso il link fornito. Inoltre, il team di gestione di MediWound sarà disponibile per incontri individuali durante il summit. Gli investitori che desiderano programmare un incontro sono invitati a contattare il proprio rappresentante Maxim.
MediWound (Nasdaq: MDWD), líder en terapias enzimáticas para la reparación de tejidos, ha anunciado su participación en el Maxim Healthcare Virtual Summit 2024. El CEO Ofer Gonen participará en una charla informal el miércoles 16 de octubre de 2024, a las 9:30 a.m. ET. La discusión será moderada por Michael Okunewitch, Analista Senior en Biotecnología de Maxim.
Las partes interesadas pueden registrarse para asistir a la charla virtual a través del enlace proporcionado. Además, el equipo de gestión de MediWound estará disponible para reuniones uno a uno durante el summit. Los inversores que deseen programar una reunión deben contactar a su representante de Maxim.
MediWound (Nasdaq: MDWD)는 조직 수리를 위한 효소 치료의 선두주자로서, 2024 Maxim Healthcare Virtual Summit에 참여할 것이라고 발표했습니다. CEO Ofer Gonen은 2024년 10월 16일 수요일 오전 9:30 ET에 가벼운 대화에 참여할 예정입니다. 이번 토론은 Maxim의 수석 생명공학 분석가인 Michael Okunewitch가 진행합니다.
관심 있는 분들은 제공된 링크를 통해 가상 대화에 참석하기 위해 등록할 수 있습니다. 또한, MediWound 경영팀은 서밋 기간 동안 개별 회의를 위해 대기하고 있습니다. 회의를 예약하고자 하는 투자자는 Maxim 담당자에게 연락해야 합니다.
MediWound (Nasdaq: MDWD), leader dans les thérapies enzymatiques pour la réparation des tissus, a annoncé sa participation au Sommet Virtuel Maxim Healthcare 2024. Le PDG Ofer Gonen participera à une discussion informelle le mercredi 16 octobre 2024, à 9h30 ET. La discussion sera animée par Michael Okunewitch, Analyste Senior en Biotechnologie chez Maxim.
Les parties intéressées peuvent s'inscrire pour assister à la discussion virtuelle via le lien fourni. De plus, l'équipe de direction de MediWound sera disponible pour des réunions individuelles pendant le sommet. Les investisseurs souhaitant planifier une réunion sont invités à contacter leur représentant Maxim.
MediWound (Nasdaq: MDWD), Marktführer in enzymatischen Therapien zur Gewebereparatur, hat seine Teilnahme am Maxim Healthcare Virtual Summit 2024 angekündigt. CEO Ofer Gonen wird am Mittwoch, den 16. Oktober 2024, um 9:30 Uhr ET an einem informellen Gespräch teilnehmen. Die Diskussion wird von Michael Okunewitch, Senior Biotechnologie-Analyst bei Maxim, moderiert.
Interessierte Personen können sich über den bereitgestellten Link für die virtuelle Gesprächsrunde anmelden. Darüber hinaus wird das Management-Team von MediWound während des Gipfels für Einzelgespräche zur Verfügung stehen. Investoren, die ein Treffen vereinbaren möchten, sollten sich an ihren Maxim-Vertreter wenden.
- None.
- None.
YAVNE, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the 2024 Maxim Healthcare Virtual Summit. The fireside chat, hosted by Michael Okunewitch, Senior Biotechnology Analyst at Maxim, will take place on Wednesday, October 16, 2024, at 9:30 a.m. ET.
To attend the virtual fireside chat, please register here. In addition, the MediWound management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact their Maxim representative to schedule a meeting.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.
MediWound’s first drug, NexoBrid®, is FDA and EMA-approved as an orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Building on its proprietary enzymatic platform, MediWound is advancing EscharEx®, a promising candidate currently in Phase III development for the debridement of chronic wounds. With distinct advantages over the current
For more information visit www.mediwound.com and follow us on LinkedIn.
| MediWound Contacts: | |
| Hani Luxenburg | Daniel Ferry |
| Chief Financial Officer | Managing Director |
| MediWound Ltd. | LifeSci Advisors, LLC |
| ir@mediwound.com | daniel@lifesciadvisors.com |
| Media Contact: | |
| Ellie Hanson | |
| FINN Partners for MediWound | |
| ellie.hanson@finnpartners.com | |
| +1-929-588-2008 | |
FAQ
When is MediWound (MDWD) participating in the 2024 Maxim Healthcare Virtual Summit?
Who will represent MediWound (MDWD) at the 2024 Maxim Healthcare Virtual Summit?
How can investors attend MediWound's (MDWD) fireside chat at the Maxim Healthcare Virtual Summit?
Are one-on-one meetings available with MediWound (MDWD) management during the 2024 Maxim Healthcare Virtual Summit?
